Market Overview The CAR T cell therapy market is aggressively expanding beyond established hematologic malignancy indications into solid tumors, autoimmune diseases, and infectious diseases that represent vastly larger addressable patient populations. Solid tumor microenvironments present unique challenges including antigen heterogeneity, immunosuppressive factors, and physical barriers that...